Understanding how certain immune cells respond to HIV in high-risk individuals
Origins and dynamics of HIV gp120 specific B cell memory in HIV negative high-risk individuals
['FUNDING_R01'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-11013181
This study is looking at how certain immune cells called B cells respond in people who are at high risk for HIV but don’t have the virus yet, to see if we can help their bodies create a stronger defense against HIV through vaccines.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-11013181 on ClinicalTrials.gov |
What this research studies
This research investigates the immune response of B cells, which are crucial for producing antibodies against HIV, in individuals who are at high risk for HIV infection but are currently HIV negative. The study focuses on the development of specific memory B cells that can recognize the HIV gp120 protein, which is essential for the virus's ability to infect cells. By analyzing the characteristics of these B cells before any exposure to HIV, the research aims to identify how a strong immune response can be generated, potentially leading to effective vaccine strategies. Participants will undergo blood tests to evaluate their B cell populations and antibody responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are HIV negative individuals who are considered at high risk for HIV acquisition.
Not a fit: Patients who are already HIV positive or those who do not fall into the high-risk category may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective HIV vaccines that better prepare the immune system to fight the virus.
How similar studies have performed: Previous studies have shown promising results in understanding B cell responses to HIV, indicating that this approach has potential for success.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KOBIE, JAMES J — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: KOBIE, JAMES J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus